Integra LifeSciences Brand Guidelines: From an MIT Artificial Skin to a Princeton Medtech Group

A surgeon, an engineer and a licence.

Integra LifeSciences was built around a single invention. English Wikipedia says that in 1969 John F. Burke, a surgeon and Harvard Medical School professor, and Ioannis V. Yannas, an MIT professor of mechanical engineering who worked on fibres and polymers, began work on a new form of artificial skin: a thin silicone top layer over a lower layer made from animal tissue. Wikipedia calls the result the first commercially reproducible artificial skin.

The company followed twenty years later. Wikipedia says Richard Caruso founded Integra in 1989, after licensing the artificial-skin technology from Harvard and MIT and acquiring Colla-tec, a subsidiary of Marion Laboratories. The company is headquartered in Princeton, New Jersey, and its shares trade on the Nasdaq under the ticker IART. Stuart Essig led the company as chief executive from 1997 to 2012, MedTech Dive reported in 2026.

The skin gave the company its name and its first major product. English Wikipedia says the U.S. Food and Drug Administration approved Integra artificial skin in 1996, for patients with extensive burns, and approved its use for reconstructive surgery of burn scars, as the Integra Dermal Regeneration Template, in 2002; it adds that the template received premarket approval for diabetic foot ulcers in 2016. In 1999, Wikipedia says, the FDA approved DuraGen, an absorbable implant used in neurosurgical and spinal procedures, which took the company into the brain and spine as well as the skin.

Buying its way into wounds, nerves and sinuses.

Integra grew mainly by acquisition. English Wikipedia lists a run of deals that shaped its wound business: in July 2015 it bought TEI Biosciences and TEI Medical and took over their SurgiMend and PriMatrix lines, PriMatrix being a dermal repair scaffold; in January 2017 it bought Derma Sciences, which brought the TCC-EZ total contact cast; and in January 2021 it bought ACell, a regenerative medicine firm.

Other deals widened the company well beyond wounds. In 2014 it bought Covidien’s Confluent Surgical line of sealants and shields and instrument lines from Medtronic; in October 2017 it bought the Codman neurosurgery business of Johnson & Johnson, whose Codman Hakim valve was developed for hydrocephalus; and in April 2024 it completed the purchase of Acclarent, an ear, nose and throat business, Wikipedia says. Earlier, in 2002, it had bought NMT, maker of the Licox brain tissue oxygen and temperature monitor. Wikipedia adds that Integra appeared on Fortune’s list of fastest-growing companies in 2018 and ranked 59th on Medical Design and Outsourcing’s 2023 list of the world’s largest medical technology companies.

Today the company presents itself in five areas on its website: neurosurgery, wound reconstruction, soft tissue reconstruction, surgical instruments and ear, nose and throat. Its wound reconstruction catalogue is grouped by material rather than by brand, with categories including engineered collagen, fetal bovine dermis, urinary bladder matrix and manuka honey. Its instrument business carries instrument brands including Jarit and Padgett. The company says hydrocephalus valves are made at its Le Locle facility in Switzerland.

Its website leads with surgeons rather than patients: hands-on training at its BioSkills Lab, staff profiles from its plants, and its presence at meetings such as the 2026 Congress of Neurological Surgeons annual meeting.

How the category presents itself.

Wound-care, ostomy and continence companies sell mostly to nurses, surgeons and pharmacists, and their visual language tends to reflect that audience. Brochures and websites in the category often favour soft-focus close-ups of skin and dressings, clean white backgrounds and pale, calm colours, with the product shown in use rather than as an object. Nurses appear again and again: at hospital bedsides, in clinics and in community care, changing a dressing or talking with a patient at home.

Ostomy and continence brands face a different task. Their users live with the products every day, so the imagery usually moves out of the clinic and into ordinary life: discreet lifestyle photography of people with a stoma swimming, hiking, travelling or at work, with the pouch rarely in view. Packaging across the category tends towards pastel tones, plain product names and clear labelling that has to read on a ward shelf and in a home bathroom alike.

The trade also has its own calendar. Companies meet clinicians at congresses such as the conference of the European Wound Management Association (EWMA) in Europe, the Symposium on Advanced Wound Care (SAWC) in the United States and the annual meeting of the Wound, Ostomy and Continence Nurses Society (WOCN), where stands, posters and education sessions carry much of a brand’s presence. Swedish Wikipedia records that Mölnlycke prepared a position document on its Safetac technology together with EWMA.

The companies in this guide range from a Swedish textile mill of 1849 and a Dijon family group to British ostomy specialists and American medical-technology firms. Each guide sets out what can be checked — who founded the company, who owns it and where it says its products are made — and separates documented facts from the company’s own claims.

Warning letters, a recall and a change at the top.

Integra’s recent history has been shaped by its plants as much as its products. The Boston facility it acquired with TEI Biosciences in 2015, which makes collagen-based devices for wound care, soft tissue repair and reconstruction, received an FDA warning letter on quality systems in 2019, MedTech Dive reported. Integra paused production there in December 2022 after an internal complaint about quality issues, recalled all products made at the site over the previous five years, and in July 2023 received a second warning letter, MedTech Dive reported in August 2023. In May 2024 the publication reported that a third-party audit had found more outstanding problems than the company expected, keeping SurgiMend and PriMatrix off the market.

The problems were not confined to Boston. After the FDA issued Form 483 observations in 2024, it sent a warning letter later that year covering three facilities that make products including cranial perforators, and in 2025 Integra recalled Codman cranial perforators, which the FDA entered in its database as Class I recalls, MedTech Dive reported in July 2025.

Leadership changed with the turbulence. Mojdeh Poul became chief executive in January 2025, after Jan De Witte announced his retirement. In May 2026 MedTech Dive reported that Stuart Essig had returned as chief executive, fourteen years after leaving the post, with Michael McBreen in a new role as chief commercial officer; Essig described Poul’s departure as a mutual decision. The publication added that the company was still working to return products to the market, and that Essig said he expected no portfolio moves in the near future and wanted to lower the company’s debt before considering further acquisitions.

For a design guide, Integra LifeSciences shows how a company named after its first invention can grow into a broad surgical group while keeping a sober, clinical voice. Compare Smith+Nephew and MiMedx. For this guide we use navy, blush and slate with a serif, an unofficial interpretation; no product or logo is reproduced.

Keep Integra LifeSciences’s identity on hand — save it to a board in the Made Good inspiration library.